Detailed Programme

Status: 01 September,, 2016

Sunday, 4 September, 2016	
08h00 - 19h00	Congress Registration
10h00 - 16h00	**Continuing Education Courses (CEC)** including coffee & lunch breaks
10h00 - 16h00 **PARIS** ELSEVIER	**CEC 1: Sponsored by ELSEVIER "Integrative Approaches to Testing and Assessment (IATA) for skin sensitization: from theory to practice"** ***Chairs:*** *Janine Ezendam, The Netherlands and Laura Rossi, Finland* Much progress has been made in the development, validation and regulatory acceptance of non-animal test methods for skin sensitisation hazard identification. For full replacement of the currently used animal tests, integration of data from multiple alternative test methods is needed to mechanistically cover the complexity of the skin sensitization process. The OECD Adverse Outcome Pathway (AOP) describes the molecular initiating event and subsequent key events of the induction of skin sensitization. This AOP is used as a mechanistic anchor to develop integrated and defined approaches to testing and assessment for skin sensitization. In this CEC, participants are informed on how non-animal test methods can be used for skin sensitization testing in the context of the REACH regulation. Furthermore, two recently published OECD guidance documents on defined and integrated approaches to testing and assessment will be presented, explaining definitions, general principles and generic examples. Case studies that illustrate different defined approaches for skin sensitization are provided and their utility for safety assessment of cosmetics is presented. The role of computational and statistical tools in integrated approaches is covered as well. Overall, this CEC course will provide the most recent knowledge on defined and integrative approaches for skin sensitization and the way they can be applied in practice. 10:00 - 10:45 **CEC 1-1** **How to use non-animal test methods for skin sensitisation in the context of REACH Regulation** <u>Laura H Rossi</u> Evaluation, European Chemicals Agency, Helsinki, Finland 10:45 - 11:30 **CEC1-2** **OECD guidance on the reporting of defined approaches and individual**

	information sources to be used within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitization Silvia Casati EURL ECVAM, Joint Research Centre, European Commission 11:30 – 11:45 Coffee Break 11:45 - 12:30 **CEC1-3** **From theory to practice: case studies illustrating different defined approaches for testing and assessment for skin sensitization** Janine Ezendam *National Institute for Public Health and the Environment (RIVM)* 12:30 – 14:00 Lunch Break 14:00 - 14:45 **CEC1-4** **Utility of integrated non-animal approaches for skin sensitisation for safety assessment of cosmetics** Sebastian Hoffmann *Consultant of Cosmetics Europe / SEH Consulting Services, Germany* 14:45 - 15:30 **CEC1-5** **Computational tools and their role in integrative approaches** Steve Enoch School of Pharmacy and Biomolecular Sciences, UK **Wrap-up and final questions** 15:30-15:45
10h00 - 16h00 **MADRID**	**CEC 2: Toxicokinetics** ***Chairs:*** *Nancy Claude, France, and Eva Cecilie Bonefeld Jorgensen, Denmark* Toxicokinetics is a science that underpins the basis of toxicology, and provides a basis for mechanistic understanding in toxicology. This session seeks to provide an overview of toxicokinetics, whilst updating on areas that are seeing significant developments. The intention is to provide information that is tailored for use in toxicology,

be it to support safety assessment of pharmaceuticals, pesticides, biocides or to optimise testing strategies in REACH. The session starts with an overview of ADME concepts, before dealing with how to choose bioanalytical methods for tox studies, and the use of micro-sampling to generate optimal information. Approaches for in vitro to in vivo extrapolation are covered, and the integration of PK information in PBPK modelling is described. Participants can expect to have an update of their general theoretical understanding of toxicokinetics, as well as a more detailed understanding of the practical application of the specific methodologies discussed.

10:00 - 10:30

CEC2-1

Basic ADME in non-clinical drug discovery & development

Richard John Weaver
Richard J. Weaver. Servier Group, France

10:30 - 11:00

CEC2-2

Applying the right level of bioanalytical method validation for PK analysis in support of preclinical (tox) studies

Philip Timmerman
Philip Timmerman, Janssen R&D, on behalf of EBF

11:00 – 11:30

Coffee Break

11:30 - 12:00

CEC2-3

Microsampling for Toxicokinetic Studies

Josephine Burnett
Department of Toxicology, Covance Laboratories Ltd, Harrogate, UK

12:00 – 13:30

Lunch Break

13:30 - 14:00

CEC2-4

In vitro kinetics in quantitative in vitro-in vivo extrapolation

Nynke I. Kramer
Institute for Risk Assessment Sciences, Utrecht University

14:00 - 14:30

CEC2-5

An Introduction to PBPK Modelling

	George Demetrius Loizou Health Risks, Health and Safety Laboratory, UK
10h00 - 16h00 **BRUSELAS CD**	**CEC 4: Evaluation of food additives in Europe: Point of the art** ***Chairs:*** *Claudia Roncanciopena, Italy, and Pr. D. Parent Massin, France* All food additives on the EU market are subject to an evaluation programme according to EU regulation N°257/2010 which is expected to be finalized by 2020 and is performed by the Additives and Nutrient Sources (ANS) Panel of EFSA. The programme started by the evaluation of food colours, preservatives and thickeners. While sweeteners has to be considered at the end of the program, the re-evaluation of aspartame has been asked by European Parliament to be considered earlier. During this workshop, the point of the art of these evaluations will be presented by member of the ANS Panel from EFSA. 10:00 - 10:30 **CEC4-1** **Principles of re-evaluation of food additives in Europe: Point of the Art of the re-evaluation of sweeteners** Aljcia Mortensen[1], Fernando Aguilar[1], Riccardo Crebelli[1], Alessandro Di Domenico[1], Maria José Frutos Fernandez[1], Paolo Colombo[2], Alexandra Tard[2], Claudia Roncancio Peña[2] [1]Scientific Panel on Food Additives and Nutrient Sources Added to Food (ANS), European Food Safety Authority (EFSA), Parma, Italy [2]European Food Safety Authority, Food Ingredients and Packaging Unit (FIP), Parma, Italy 10:30 - 11:00 **CEC4-2** **Food colours: Point of the Art evaluation** Agneta Oskarsson[1], Ruud Woutersen[2], Jean Charles Leblanc[2], Peter Moldeus[2], David Gott[2], Ursula Gundert Remy[2], Federica Lodi[3], Stravoula Tasiopoulou[3] [1]Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden [2]Scientific Panel on Food Additives and Nutrient Sources Added to Food (ANS), European Food Safety Authority (EFSA), Parma, Italy [3]European Food Safety Authority, Food Ingredients and Packaging Unit (FIP), Parma, Italy 11:00 – 11:30 Coffee Break 11:30 - 12:00 **CEC4-3** **Thickeners and preservatives: Point of the Art of the re-evaluation**

	Dominique Parent Massin[1], Birgit Dusemund[1], Oliver Lindtner[1], Pasquale Mosesso[1], Pierre Galtier[1], Anna Christodoulidou[2], Juho Lemmetyinen[2] [1]Scientific Panel on Food Additives and Nutrient Sources Added to Food (ANS), European Food Safety Authority (EFSA), Parma, Italy [2]European Food Safety Authority, Food Ingredients and Packaging Unit (FIP), Parma, Italy 12:00 – 13:30 Lunch Break 13:30 - 14:00 **CEC4-4** **Emulsifiers: Point of the Art evaluation** Matthew C Wright[1], Ivan Stankovic[2], Ine Waalkens Berendsen[3], Ruud A Woutersen[3], Maged Younes[3], Ana Maria Rincon[4], Dario Battacchi[4] [1]Institute Cellular Medicine, Newcastle University, UK [2]Faculty of Pharmacy, University of Belgrade, Serbia [3]Scientific Panel on Food Additives and Nutrient Sources Added to Food (ANS), European Food Safety Authority (EFSA), Italy [4]European Food Safety Authority, Food Ingredients and Packaging Unit (FIP), Italy
10h00 - 16h00 **BRUSELAS EF**	**CEC 5: In vivo chemical genotoxin exposure and DNA damage in humans measured using the lymphocyte cytokinesis-block micronucleus (CBMN) assay** ***Chairs:*** *Michael Fenech, Australia, and Nina Holland, USA* The lymphocyte cytokinesis-block micronucleus (CBMN) assay is one of the most commonly used methods to measure chromosomal DNA damage in human populations and has been shown to be associated prospectively with cancer risk. However, there is currently considerable debate about which biomarker assays are suitable for measuring the DNA damage effects of in vivo exposure to chemical genotoxins in humans. Over the past 30 years at least 295 papers have reported case/control studies on the use of the lymphocyte cytokinesis-block (CBMN) assay to measure DNA damage in humans exposed to various types of chemicals that may be genotoxic in vivo. However this large body of literature has never been comprehensively examined to determine whether the CBMN assay is effective in detecting DNA damage induced by in vivo exposure to different classes of known chemical genotoxins in human populations. In this workshop we shall be reporting the outcomes of systematic reviews and meta-analyses of these bio-monitoring studies of exposure to different classes of chemical genotoxins using the lymphocyte CBMN assay and comparing its performance to detect induced DNA damage relative to other genotoxicity assays that are also commonly used. Furthermore, current knowledge on the mechanisms by which chemical genotoxin exposure may cause the induction of micronuclei and other nuclear anomalies in vivo and ex vivo will be discussed. The possibility of further improving the utility of the lymphocyte CBMN assay to measure DNA damage caused by chemical genotoxin exposure will be explored. 10:00 - 10:30

CEC5-1

Pesticides and herbicides - Results of a systematic review of human exposure studies using the lymphocyte CBMN assay

Claudia Bolognesi[1], Nina Holland[2]
[1]Environmental Carcinogenesis Unit, IRCCS AUO San Martino IST-
National Cancer Research Institute, Genova, Italy
[2]Nina Holland, School of Public Health, University of California, Berkeley, California, USA

10:30 - 11:00

CEC5-2

Heavy metals: Results of a systematic review of human exposure studies using the lymphocytes micronucleus assay

Siegfried Knasmueller, Miroslav Mišík, Michael Kundi, Georg Wultsch, Armen Nersesyan
Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

11:00 – 11:30

Coffee Break

11:30 - 12:00

CEC5-3

Exposure to petroleum, petroleum derivatives PAHs and traffic fumes - Results of a systematic review of human studies using the lymphocyte CBMN assay

Radim Sram
Institute of Experimental Medicine AS CR, Prague, Czechia

12:00 – 13:30

Lunch Break

13:30 - 14:00

CEC5-4

Biomonitoring of genotoxic effects for human exposure to nanomaterials: The challenge ahead

Micheline Kirsch Volders, Laetitia Gonzalez

Laboratory of cell genetics, Vrije Universiteit Brussel, Brussels, Belgium

14:00 - 14:30

CEC5-5

All other chemicals – Results of systematic reviews of human exposure studies using the lymphocyte CBMN assay

Stefano Bonassi

	Clinical and Molecular Epidemiology IRCCS San Raffaele Pisana, Rome, Italy
10h00 - 16h00 **BRUSELAS GH**	**CEC 6: Green toxicology - A complementary 'qua non' activity for the sustainable development of chemicals and drugs in the 21st century** ***Chairs:*** *Harald Krug, Switzerland and Bensu Karahalil, Turkey* Green toxicology is the application of predictive toxicology to the production of chemicals with the specific intent of improving their design for hazard reduction. The twelve principles of green chemistry outline a strategy to reduce hazard through molecular and process design. Reducing toxicity is at the core of green chemistry and sustainability, therefore the input of toxicologists early in the chemical enterprise is essential to inform the choices of molecular designers in selecting less hazardous design strategies. Information derived from mechanistic and computational toxicology combined forms the nexus between toxicology and green chemistry. Each group is trained to examine, understand and describe aspects of the structure hazard relationship from a narrow perspective. This course will provide a forum for collaboration among academia and industry working in complementary fields to discover common ground in the quest for safer chemicals. 10:00 - 10:30 **CEC6-1** **Twenty first century toxicology and safer chemical design** Thomas Hartung Johns Hopkins Bloomberg School of Public Health, USA 10:30 - 11:00 **CEC6-2** **How the Greenpeace Detox campaign drives the fashion industry towards sustainable supply chains** Anne Bonhoff UL Environment 11:00 – 11:30 Coffee Break 11:30 - 12:00 **CEC6-3** **Green toxicology and chemistry: Hand in glove** Bennard Van Ravenzwaay, Hennicke Kamp, Robert Landsiedel, Tzutzuy Ramirez all authors BASF SE, Ludwigshafen/Germany 12:00 – 13:30 Lunch Break

	13:30 - 14:00 **CEC6-4** **Green Toxicology – The Future in sustainability in chemical and material development** Harald F. Krug Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland & NanoCASE GmbH, Engelburg, Switzerland
16h00	**Opening of the Exhibition**
17h00 - 19h00 **AUDITORIUM I**	**Opening Ceremony- AUDITORIUM I** ***Chair:*** Aristidis Tsatsakis, President of EUROTOX, Greece 17.00-17.30 **Welcome Address** by Ali Esat Karakaya President of the EUROTOX 2016 Congress, Turkey **Welcome Address** by Aristidis Tsatsakis President of EUROTOX, Greece 17:30 – 17:45 **EUROTOX Merit Award Ceremony** 18:00 – 19:00 **Opening Lecture** ***Chair***: *Ali Esat Karakaya, Turkey* **Nanomedicines for neurological disorders** Turgay Dalkara *Hacettepe University, Institute of Neurosciences, Ankara, Turkey*
19h00 - 21h00	**Welcome Reception- EXHIBITION AREA**
Monday, 5 September, 2016	
08h00 - 19h00	Congress Registration / 08h30 – 18h00 Exhibition
08h30 - 09h30 **AUDITORIUM I**	**Keynote Lecture** ***Chair****: Ruth Roberts, UK* **K-1** **Evolution of Computational Toxicology: From Primitive Beginnings to Sophisticated Application** Russell S. Thomas *Environmental Protection Agency, USA*
09h30 - 10h00	Coffee Break, Exhibition and Poster Viewing
10h00 - 12h00 **AUDITORIUM II**	**Symposium S01: Adverse drug reactions: Mechanisms and preclinical testing** ***Chairs:*** *Hilmi Orhan, Turkey, and Fred Guengerich, USA* **S01-1** **Mechanisms of adverse drug reactions: Metabolic and others**

	Frederick Peter Guengerich Vanderbilt University School of Medicine, Nashville, TN, United States **S01-2** **Role of glutathione transferases and quinonoxidoreductases in protection against reactive drug metabolites** Jan N.M. Commandeur VU University Amsterdam, Molecular Toxicology, Amsterdam, The Netherlands **S01-3** **From intravital imaging to in vitro test systems** Jan G. Hengstler Leibniz Research Centre for Working Environment and Human Factors IfADo -Dortmund - Germany **S01-4** **Involvement of mitochondria in drug-induced toxicities** Hilmi Orhan Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ege University, Izmir, Turkey
10h00 - 12h00 **AUDITORIUM III**	**Symposium S02: A multidisciplinary approach for novel developmental neurotoxicity risk assessment contributing to the AOP concept** ***Chairs**: Eugenio Vilanova, Spain and Anna Price, Italy* **S02-1** **Systematic review on methods for developmental neurotoxicity evaluation based on an EFSA Report** Andrea Terron[1], Stefan Masjosthusman[2], Henrich Alm[2], Jenny Baumann[2], Lieve Geerts[4], Helen Hakansonn[3], Hilda Witters[4], Ellen Fritsche[2] [1]European Food Safety Authority (EFSA), Parma, Italy [2]IUF, Dusseldorf, Germany [3]Karolinska Institutet, Stockholm, Sweden [4]VITO, Boeretang, Belgium **S02-2** **3D Models and omics approaches to study developmental neurotoxicity** Helena T Hogberg[1], Mounir Bouhifd[2], Ozge Cemiloglu Ulker[3], Rita De Cassia Da Silveira E Sa[4], Georgina Harris[1], Andre Kleensang[1], Alexandra Maertens[1], David Pamies[1], Lena Smirnova[1], Liang Zhao[1], Hartung Thomas[1] [1]Center for Alternatives to Animal Testing, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA [2]Joint Research Center, European Commission, Ispra, Italy [3]Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey [4]Department of Physiology and Pathology, Federal University of Paraiba, Paraiba,

	Brazil **S02-3** **Species-specific, comparative functional and 'omics' analyses of developing human, rat and mouse primary neurospheres** Ellen Fritsche IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany **S02-4** **From simple in vitro test to complex models: the example of developmental toxicity of organophosphorus compounds** Eugenio Vilanova, Andrea C. Romero, David Pamies, Carmen Estevan, Miguel A. Sogorb Unit of Toxicology, Institute of Bioengineering, Miguel Hernandez University of Elche, Alicante-Spain **S02-5** **Using mechanistic information in application of an Adverse Outcome Pathway (AOP) concept for developmental neurotoxicity evaluation** Anna Price Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Italy
10h00 - 12h00 **MADRID**	**Workshop W01: Enhancing the quality of predictions for developmental toxicity based on alternative methods** ***Chairs:*** *Bennard van Ravenzwaay, Germany and Aldert Piersma, The Netherlands* **W01-1** **A transcriptomic approach for a mechanistic insight into developmental toxicity of azoles in the rat Whole Embryo Culture** Myrto Dimopoulou[1], Aart Verhoef[2], Bennard Van Ravenzwaay[3], Ivonne M.C.M. Rietjens[1], Aldert H. Piersma[2] [1]Division of Toxicology, Wageningen University, the Netherlands [2]National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands [3]BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany **W01-2** **Screening of developmental toxicity – Validation and predictivity of the zebrafish embryotoxicity assay (ZETA) and strategies to optimize de-risking developmental toxicity of drug candidates** Eckart Krupp Sanofi-Aventis Deutschland GmbH, Preclinical Safety, Frankfurt, Germany **W01-3** **Crack the egg – Improvement in the use of chicken embryos to predict developmental toxicity**

	Burkhard Flick, Tzutzuy Ramirez, Bennard Van Ravenzwaay Department of Experimental Toxicology and Ecology, BASF SE, Ludwigshafen, Germany **W01-4** **Pathway specific assay (1) The assessment of angiogenesis/vasculogenesis in the context of developmental toxicity** Tuula Heinonen, Outi Huttala, Tarja Toimela Ficam, University of Tampere, Finland **W01-5** **Computational modeling and simulation of developmental toxicity** Thomas B Knudsen National Center for Computational Toxicology, USA
10h00 - 12h00 **PARIS**	**Workshop W02: Improving chemicals risk assessment with refined exposure characterisation** ***Chairs:*** *Jim Bridges, UK, and Helmut Greim, Germany* **W02-1** **Improving chemical risk assessment through tiered and targeted application of exposure assessment** Gerlienke Schuur A.G. Schuur **W02-2** **Experiences from the ECETOC TRA tool, 2004-2016** Chris Money Cynara Consulting, Brockenhurst, UK **W02-3** **Refining exposure data acquisition and application in higher tier consumer assessments, W2(10)** Natalie Von Goetz Institute of Chemical and Bioengineering, ETH Zurich, Switzerland **W02-4** **Modelling Total Exposure to Chemicals from Multiple Sources** Sarah Anne Tozer Procter & Gamble, Egham, Surrey, UK **W02-5** **How to improve the quality of exposure information needed for REACH processes?**

	Andreas Ahrens Registration Directorate, European Chemicals Agency, Helsinki, Finland
12h00 - 14h00	Lunch Break, Exhibition & Poster Session I-**POSTER AREA**
12h00 - 13h00 **AUDITORIUM II**	**HESI CITE Lecture** ***Chair:*** *Raegan O'Lone* **K-2** **The use of in vitro models: On the road from hazard to risk assessment** Martin van den Berg Institute for Risk Assessment Sciences (IRAS) & Utrecht University, The Netherlands
13h00 - 14h00 **AUDITORIUM I**	**Glyphosate Task Force (GTF) Symposium**
13h00 - 14h00 **BRUSELAS ROOM GH**	**HESI roundtable discussion** **Chairs:** *Ruth Roberts and Raegan O'Lone* The use of replacement in vitro models in risk assessment
14h00 - 16h00 **AUDITORIUM I**	**Symposium S03: Microbiome, nutrition, and immune-mediated diseases** ***Chairs:*** *Berran Yucesoy, USA and Marc Pallardy, France* **S03-1** **Complex interplay between the immune system and the infant gut microbiota: Potential health implications** Maria Jenmalm Department of Clinical and Experimental Medicine, Unit of Autoimmunity and Immune Regulation, Linköping University, Linköping, Sweden **S03-2** **Early-life nutrition, gut microbiota and allergies** Hania Szajewska The Medical University of Warsaw, Department of Pediatrics **S03-3** **Diet, gut microbiota, and immunometabolic dysfunction** Alexander R Moschen Department of Medicine, Division of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria **S03-4** **Skin microbiome, inflammatory and allergic skin diseases** Georgios Stamatas Emerging Science & Innovation, R&D, Johnson & Johnson Santé Beauté France, Issy-les-Moulineaux, France
14h00 - 16h00 **AUDITORIUM II**	**Workshop W05 Rat Carcinogenicity Studies – Can they be replaced?** ***Chair:*** *Thomas Weiser, Switzerland, and Ruth Roberts, UK*

	W05-1 **Overview of pharmacology-induced mechanisms of carcinogenesis** Jan Willem Van Der Laan[1], Peter Kasper[2], Beatriz Silva Lima[3], David Jones[4], Markku Pasanen[5] [1]Section on pharmacological, The Netherlands. [2]Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany [3]Universidade de Lisboa, Faculty of Pharmacy, Lisbon, Portugal [4]Medicines and Healthcare products Regulatory Agency, London, United Kingdom [5]University of Eastern Finland, Faculty of Health Sciences, School of Pharmacy, Kuopio, Finland **W05-2** **Revision of the current ICH S1 guidance on rodent carcinogenicity testing: Where do we stand?** Peter Kasper Federal Institute for Drugs and Medical Devices (BfArM) **W05-3** **Carcinogenicity Assessment Documents and the added value of "Weight-of-Evidence" factors - an industry perspective** Lutz Mueller F. Hoffmann-La Roche Innovation Center, Basel, Switzerland **W05-4** **Future Directions in Carcinogenicity Testing for Pharmaceuticals** Michael Graziano Drug Safety Evaluation at Bristol-Myers Squibb
14h00 - 16h00 **AUDITORIUM III**	**Symposium S05: The H2020 EU-ToxRisk project: A novel flagship program for mechanism-based safety sciences and risk assessment** ***Chair*:** *Hennicke Georg Kamp, Germany, and Joana Mirana, Portugal* **S05-1** **The EU-ToxRisk project: A European flagship program for mechanism-based safety sciences and risk assessment** Hennicke Georg Kamp BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany **S05-2** **Industry perspective on AOP-based toxicological approaches: from knowledge to implementation** Hennicke Georg Kamp BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany

	S05-3 **Integrative knowledge management and modelling supporting the EU-ToxRisk project** Ferran Sanz IMIM – Universitat Pompeu Fabra Barcelona, Spain **S05-4** **Assessment of quantitative AOP key events in human hepatocytes using transcriptomics biomarkers** Jan G Hengstler Department of Systems Toxicology, IfADo at TU Dortmund, Germany **S05-5** **Development and reproductive toxicity: Advanced model systems and quantitative risk assessment** Dinant Kroese[1], Andre Wolterbeek[2], Bart Van De Burg[3] [1]Department Risk Analysis of Products In Development, TNO Zeist, The Netherlands [2]Triskelion B.V., a TNO Company, Zeist, The Netherlands [3]BioDetection Systems BV, Amsterdam, The Netherlands
14h00 - 16h00 **MADRID**	**Workshop W03: Mass Spectrometry Imaging as investigative tool for molecular toxicology** ***Chairs:*** *Stefan Platz, UK and Richard Goodwin, UK* **W03-1** **Mass spectrometry imaging in drug discovery and development** Richard Goodwin Pathology Sciences, Drug Safety & Metabolism, AstraZeneca UK **W03-2** **Investigating drug-induced toxicity in tissue samples using mass spectrometry imaging** Anna Nilsson[1], Mohammadreza Shariatgorji[1], Richard Goodwin[2] [1]Department of Pharmaceutical Biosciences, Biomolecular Imaging and Proteomics, Uppsala University, Uppsala, Sweden [2]AstraZeneca, Drug Safety and Metabolism, Cambridge, UK **W03-3** **Ambient Ionization Mass Spectrometry – From the Origins to Molecular Pathology Applications** Renata Filipe-Soares *Imperial College, UK* **W03-4** **Target organ toxicity – application of MSI**

	John Swales Pathology Sciences, AstraZeneca, UK **W03-5** **Moving MS(i) closer to surgery: The need to improve pre-, intra- and post-operative clinical diagnostics** Tiffany Porta, Keely Pierzchalski, Klara Scupakova, Anne L. Bruinen, Florian P. Y. Barré, Pierre Maxence Vaysse, Flora Olivier, Benjamin Balluff, Berta Cillero-Pastor, Ron M. A. Heeren M4I institute, University of Maastricht, Maastricht, The Netherlands
14h00 - 16h00 **PARIS**	**Workshop W04: Protein targets of reactive intermediates: Linking chemistry to biology and adverse outcome** ***Chairs:*** *Angela Mally, Germany, and Hilmi Orhan, Turkey* **W04-1** **Introduction** Angela Mally *University of Würzburg, Würzburg, Germany* **W04-2** **Targets and consequences of alkylation damage by reactive electrophiles** Angela Mally Department of Toxicology, University of Würzburg, Würzburg, Germany **W04-3** **The expanding landscape of the thiol redox proteome** Jing Yang National Center for Protein Sciences, Beijing **W04-4** **Modification of cysteine residues by cyclopentenone prostaglandins in the elucidation of redox regulation of protein function** Dolores Pérez Sala Department of Chemical and Physical Biology, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain **W04-5** **Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration** Marzia Perluigi Department of Biochemical Sciences, Sapienza University of Rome
16h00 - 17h00	Coffee Break Sponsored by ELSEVIER, Exhibition & Poster Viewing

ELSEVIER	
17h00 - 19h00 **AUDITORIUM I**	**Symposium S06: Nanosafety: Present and Future** ***Chairs:*** *Kai Savolainen, Finland, and Flemming R. Cassee, The Netherlands* **S06-1** **Predicting of toxicity of engineered nanomaterials** Kai Savolainen Finnish Institute of Occupational Health **S06-2** **Immunotoxic and pulmonary effects of engineered nanomaterials** Harri Alenius Department of Bacteriology and Immunology, Helsinki University, Helsinki, Finland **S06-3** **Innovation and Model Organisms for the Environmental Hazard Assessment of Engineered Nanomaterials** Richard D Handy School of Biological Sciences, Plymouth University, United Kingdom **S06-4** **Developmental toxicity of engineered nanomaterials** Karin S. Hougaard[1], Jitka S. Hansen[1], Petra Jackson[1], Zdenka O. Kyjovska[1], Anne Mette Z. Boisen[1], Carole Yauk[2], Sabina Halappanavar[2], Keld A. Jensen[1], Håkan Wallin[1], Sandra Goericke Pesch[3], Astrid Skovmand[1], Ulla Vogel[1] [1]Danish Nanosafety Centre, National Research Centre for the Working Environment, Copenhagen, Denmark [2]Environmental Health Science and Research Bureau, Health Canada, Ottawa, Canada [3]Veterinary Reproduction and Obstetrics, Department of Large Animal Sciences, University of Copenhagen, Denmark **S06-5** **Dose metric for the prediction of toxicity of nanomaterials** Flemming R Cassee, Hedwig M Braakhuis, Margriet V Park, Agnes G Oomen, Ilse Gosens, Wim H De Jong National Institute for Public Health and the Environment (RIVM), The Netherlands
17h00 - 19h00 **AUDITORIUM II**	**Symposium S07: Safety aspects of natural compounds in dietary supplements** ***Chairs:*** *Janine Ezendam, The Netherlands and Majorie van Duursen, The Netherlands*

	S07-1 **Adverse effects of Plant Food Supplements and botanical preparation: data collected during the EU project PlantLIBRA** Patrizia Restani[1], Alessandro Ceschi[2], Gianfranco Frigerio[1], Francesca Colombo[1], Saskia Lüde[2], Hugo Kupferschmidt[2], Chiara Di Lorenzo[1] [1]Dept. Pharmacological and Biomolecular Sciences [2]National Poisons Centre, Tox Info Suisse, Associated Institute of the University of Zurich, Zurich, Switzerland **S07-2** **Natural compounds in dietary supplements: Female reproductive health hazard assessment *in vitro*** Majorie Van Duursen, Sandra Nijmeijer, Kamila Solak, Martin Van Den Berg Toxicology Division, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands **S07-3** **Quality guidelines for ensuring safety of botanical ingredients and final products** Hartwig Sievers PhytoLab GmbH & Co. KG, Germany **S07-4** **Regulations of food supplements** Patrick Coppens EAS Strategies, Brussels, Belgium
17h00 - 19h00 **AUDITORIUM III**	**Symposium S08: Role of endocrine disruptors in immune mediated disorders** ***Chairs:*** *Emanuela Corsini, Italy and Marc Pallardy, France* **S08-1** **Prenatal glucocorticoids: Consequences for the offspring's immunity** Eva Tolosa, Christina Gehbauer, Anna Gieras, Ines Diepenbruck Department of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany **S08-2** **Exposure to endocrine disruptors accelerates diabetes type 1 development in NOD mice via impaired macrophage function** Johanna Bodin[1], Anette Kocbach Bølling[2], Rune Becher[2], Frieke Kuper[3], Martinus Løvik[4], Unni Cecilie Nygaard[1] [1]Department of Toxicology and Riskassessment, Norwegian Institute of Public Health, Oslo, Norway [2]Department of Air Pollution and Noise, Norwegian Institute of Public Health, Oslo, Norway

	[3]TNO Nutrition and Food Research, Zeist, The Netherlands [4]Department for Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University for Science and Technology, Trondheim, Norway **S08-3** **Glucocorticoid receptor disruptors and immune functions** Ivana Klopčič Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia **S08-4** **Gene signatures in human leukocytes exposed to endocrine disruptors** Greet Schoeters[1,2,3], Sylvie Remy[2], Nathalie Lambrechts[1], Britt Wens[1] [1]Health Department, VITO, Mol, Belgium [2]Biomedical Dept. University of Antwerp, Antwerp, Belgium [3]Environmental Medicine, Public Health department, Southern Denmark University, Odense, Denmark
17h00 - 19h00 **MADRID**	**Symposium S04: DNA damage and repair in Cancer: From bench to clinic** ***Chairs:*** *Miral Dizdaroglu, USA and Sinan Süzen, Turkey* **S04-1** **Coordination during the stepwise process of base lesion DNA repair** Samuel H. Wilson Genome Integrity and Structural Biology Laboratory, NIH-NIEHS, Research Triangle Park, NC, USA **S04-2** **Mitochondrial dysfunction in DNA repair defective disorders: mechanisms and pathological relevance** Eugenia Dogliotti Istituto Superiore di Sanità, Rome, Italy **S04-3** **Genomic uracil – Important carcinogenic mutagen but normal intermediate in adaptive immunity** Hans Einar Krokan, Geir Slupphaug, Pål Sætrom, Antonio Sarno, Anastasia Galashevskaya, Maria Brenner Lundbæk, Per Arne Aas, Ruth Haaland Krokan, Nina Beate Liabakk, Henrik Sahlin Pettersen, Mirta M. Sousa, Berit Doseth, Bodil Kavli Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway **S04-4** **Dissecting base excision repair in breast cancer for personalization of therapy** Srinivasan Madhusudan *University of Nottingham, Nottingham, UK*

	S04-5 **Inhibition of DNA glycosylases in development of cancer therapeutics** Miral Dizdaroglu[1], Aaron C. Jacobs[2], Marcus J. Calkins[2], Ajit Jadhav[3], Dorjbal Dorjsuren[3], David Maloney[3], Anton Simeonov[3], Nathan Donley[2], Pawel Jaruga[1], Erdem Coskun[1], Amanda K. Mccullough[2], Stephen Lloyd[2] [1]National Institute of Standards and Technology, Gaithersburg, Maryland, USA [2]Oregon Health and Science University, Portland, Oregon, USA [3]National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA
17h00 - 19h00 **PARIS**	**Workshop W06: Use and misuse of the TTC concept in risk assessment** ***Chair*:** *Dieter Schrenk, Germany, and Helena Kandarova, Slovakia* **W06-1** **Twelve years of TTC (of genotoxic carcinogens) – A success story?** Dieter Schrenk Food Chemistry and Toxicology, University of Kaiserslautern **W06-2** **TTC and "unknowns", e.g. in food contact materials** Benoit Schilter Nestlé Research Center **W06-3** **TTC and herbal preparations** Olavi Pelkonen Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland **W06-4** **Is the use of a default TTC for impurities warranted?** Lutz Mueller F. Hoffmann-La Roche Innovation Center, Basel, Switzerland
19h30 – 21h00	AstraZeneca Reception-*by invitation only* **NH COLLECTION HOTEL**
Tuesday, 6 September, 2016	
08h00 - 18h30	Congress Registration | 08h30 – 18h00 Exhibition
08h00 - 09h30 **AUDITORIUM I**	**Keynote Lecture Bo Holmstedt Memorial Fund** ***Chair:*** *Herman Autrup, Denmark* **K-3** **Assessment of functional impairment and transcriptome changes based on human stem cell derived developmental toxicity tests**

	Marcel Leist In vitro toxicology and biomedicine, University of Konstanz, Konstanz, Germany
09h30 - 10h00	Coffee Break, Exhibition and Poster Viewing
10h00 - 12h00 **AUDITORIUM I**	**Symposium S09: Integrating epidemiology and experimental toxicology to improve pesticide risk assessment** ***Chairs:*** *Aristidis Tsatsakis, Greece and Antonio Hernandez-Jerez, Spain* **S09-1** **Integrating epidemiological, mechanistic and experimental toxicology data for pesticide risk assessment** Antonio F Hernández Jerez[1], Fernando Gil[1], Marina Lacasaña[2] [1]Dept. Legal Medicine and Toxicology. University of Granada School of Medicine, Granada (Spain) [2]Escuela Andaluza de Salud Pública, Granada (Spain), CIBERESP, ibs. GRANADA **S09-2** **Pesticides and Parkinson's disease – What is the evidence from epidemiological and experimental studies?** Martin F. Wilks Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland **S09-3** **Using large animal models and clinical research to understand organophosphorus toxicity and treatment** Michael Eddleston Pharmacology, Toxicology & Therapeutics, University of Edinburgh **S09-4** **Neurodevelopmental toxicity of organophosphate pesticides: Mechanistic data and epidemiological studies** Félix Carvalho UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Portugal **S09-5** **Disturbed extracellular matrix homeostasis: Identification of novel biomarkers for pesticide-induced toxicity?** Dragana Nikitovic Medical School, University of Crete, Heraklion, Greece
10h00 - 12h00 **AUDITORIUM II**	**Workshop W07: Application of human-based system toxicology for preclinical safety assessment of pharmaceuticals** ***Chairs:*** *Rob Stierum, The Netherlands, and Geny Groothuis, The Netherlands*

	W07-1 **A systems toxicology approach for liver toxicity: the ASAT approach and infrastructure** Eugene van Someren[1], Jennifer Mccormack[1], Gino Kalkman[1], Janine Ezendam[2], Evelyn Olthof[2], Danyel Jennen[3], Dinant Kroese[1], Rob Stierum[1] [1]RAPID, TNO, Zeist, The Netherlands [2]RIVM, Bilthoven, The Netherlands [3]Department of Toxicogenomics, Maastricht University, Maastricht, The Netherlands **W07-2** **The adverse outcome pathway for cholestatic liver injury: From mechanisms to predictive human toxicology** Mathieu Vinken Department of In Vitro Toxicology, Vrije Universiteit Brussel, Belgium **W07-3** **Development of a mechanistic biokinetic model describing hepatic bile acid handling to predict possible cholestatic effects of drugs** Karl M. Weigand[1], Sylvia Notenboom[2], Johannes H. Proost[2], Marola M. Van Lipzig[3], Evita Van De Steeg[3], Petra H. Van Den Broek[1], Rick H. Greupink[1], Frans G. Russel[1], Geny M. Groothuis[2] [1]Department of Pharmacology and Toxicology, Radboud university medical center, Nijmegen, the Netherlands [2]Division of Pharmacokinetics Toxicology and Targeting, Department of Pharmacy, University of Groningen, Groningen, the Netherlands [3]TNO, the Netherlands **W07-4** **Mechanistic modeling of drug-induced cholestasis: Clinical relevance** Kim L. R. Brouwer UNC Eshelman School of Pharmacy and Curriculum in Toxicology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA **W07-5** **Prediction of safety with human data only: A Pharma industry perspective** Mario Monshouwer Preclinical Development & Safety, Janssen Pharmaceuticals, Beerse, Belgium
10h00 - 12h00 **AUDITORIUM III**	**Workshop W08: Safety Requirements for Biosimilars** ***Chairs:*** *Nurşen Başaran, Turkey, and Semra Şardaş, Turkey* **W08-1** **Risk Management Plans for Biosimilar Drugs** Semra Sardas Department of Pharmaceutical Toxicology, Marmara University, Istanbul, Turkey

	W08-2 **Challanges and key points of Biologics on Efficacy** Kimberly Greco *Amgen, USA* **W08-3** **Policy considerations for interchangeability and substitution** Baerbel Grossmann Sanofi Aventis, France **W08-4** **Pharmacovigilance and traceability of biological products** Keith Watson Biologics Strategic Development, Abbvie, Maidenhead, Berkshire, SL6 4UB
12h00 - 13h00 **MADRID**	**EUROTOX-SOT Debate** **Topic: Preclinical (Safety) Toxicology Testing Predicts the Clinical Outcome** ***Chairs:*** *Patricia E. Ganey, USA, and Mümtaz İşcan, Turkey* **D-01** **Preclinical (Safety) Toxicology Testing Predicts the Clinical Outcome** Ruth A Roberts[1], Thomas Monticello[2] [1]ApconiX, Alderley Park [2]Amgen Inc, California
12h00-14h00 **POSTER AREA**	Poster Session II
13h00 - 14h00	Lunch Break & Exhibition Viewing **Organovo Industry-Sponsored Symposium / PARIS** **"3D Bioprinted Human Liver and Kidney Tissues for Toxicology and Disease Modeling"** Deb Nguyen Senior Director, R&D, Tissue Applications, Organovo
14h00 - 15h00 **AUDITORIUM I**	**Keynote Lecture** ***Chair:*** *Asuman Karakaya* **K-4** **Genetics and Epigenetics of Liver Cancer** Mehmet Öztürk Dokuz Eylül University, Izmir International Biomedicine and Genome Institute, Izmir, Turkey
15h00 - 16h00	Coffee Break, Exhibition & Poster Viewing

16h00 - 18h00 **AUDITORIUM I**	**Oral Communication Session 1** (10 min presentations) ***Chairs:*** *Eren Özçağlı, Turkey and Emanuela Corsini, Italy* **OSC01-009** **Development of an {in vitro} inhalation toxicity test using the EpiAirway model for improved protection of human health** P. J. Hayden[1], G. R. Jackson, Jr.[1], A. Hunter[1], S. Coughlin[1], A. Maione[1], S. Letasiova[2], H. Kandarova[2] [1]MatTek Corporation, Ashland, MA, USA [2]MatTek In Vitro Life Science Laboratories, Bratislava, Slovak Republic **OSC02-011** **In vitro validation of in vivo assessment of toxicity and antidotes to Cleisthanthus collinus poisoning -a common suicidal phytotoxin in India** G. S. Chandra Pharmacovigilance Laboratory For Animal Feed And Food Safety centre For Animal Health Studies, Tanuvas, madhavaram Milk Colony, chennai – 600 051. tamilnadu, India **OSC01-008** **Measuring apoptosis in real-Time by linking luciferase fragments to annexin V** T. Riss[1], K. Kupcho[1], J. Shultz[1], J. Hartnett[1], R. Hurst[1], W. Zhou[2], A. Niles[1] [1]Promega Corporation, Madison, Wisconsin, USA [2]Promega Biosciences, San Luis Obispo, California, USA **OSC02-006** **Evaluation of read-across argumentation according to the ECHA Read-Across Assessment Framework (RAAF)** A. Richarz, E. Berggren, A. Worth European Commission Joint Research Centre, IHCP, Systems Toxicology Unit & EURL ECVAM, Ispra, Italy **OSC01-010** **Exposome analysis of polyaromatic hydrocarbons** D. Sarigiannis[1], S. Karakitsios[1], E. Handakas[1], A. Gotti[2] [1]Environmental Engineering Laboratory, Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece [2]Environmental Health Engineering, Institute of Advanced Study, Pavia, Italy

OSC02-001

Mercury Human health risk assessment among Lebanese youth

H. R. Dhaini[1], P. J. Obeid[2], S. A. Fares[3], G. N. Farhat[4], B. El Khoury[2], R. M. Nassif[5]
[1]Department of Environmental Health, American University of Beirut, Beirut, Lebanon
[2]Department of Chemistry, University of Balamand, Al Kurah, Lebanon
[3]Hariri School of Nursing, American University of Beirut, Beirut, Lebanon
[4]Hubert Department of Global Health, Emory University, Atlanta, Georgia, USA
[5]Medical Laboratory Sciences Program, University of Balamand, Beirut, Lebanon

OSC02-003

Thresholds of Toxicological Concern – Overview of ongoing scientific developments

S. Escher[4], C. Turek[1], S. Campos[2], J. Edwards[3], , P. Ferret[5], N. Höfer[6], K. Kosemund[7], J. Schnabel[8], B. Van Ravenzwaay[9], H. M. Hollnagel[10]
[1]Corporate drug safety, WALA Heilmittel GmbH, Bad Boll, Germany
[2]Food Contact Materials, The Coca-Cola Company, Brussels, Belgium
[3]NIC-RD/HN Toxicology and Kinetics, DSM Nutritional Products Ltd, Kaiseraugst, Switzerland
[4]Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM), Hannover, Germany
[5]Pierre Fabre Dermo-Cosmétique, Toulouse, France
[6]Südzucker AG, Mannheim, Germany
[7]Global Product Stewardship, Central Product Safety, Procter & Gamble Service GmbH, Schwalbach am Taunus, Germany
[8]Givaudan Schweiz AG, Kemptthal, Switzerland
[9]BASF SE, Ludwigshafen, Germany
[10]Toxicology and Environmental Research & Consulting, Dow Europe GmbH, Horgen, Switzerland

OSC02-004

Concentration-response analysis of high throughput data obtained in embryos cultured in vitro in presence of a binary mixture of two antifungal azoles (triadimefon and flusilazole)

F. Metruccio[1], M. Battistoni[2], F. Di Renzo[2], A. Moretto[3], E. Menegola[2]
[1]ICPS, ASST Fatebenefratelli Sacco, Milano- Italy
[2]Università degli Studi di Milano, Dipartimento di Bioscienze, Milano-Italy
[3]Università degli Studi di Milano, Dipartmento di Scienze Biomediche e Cliniche, Milano- Italy

OSC01-003

The pulmonary toxicity in nanoscale carbon black-exposed workers

	R. Zhang[1], Z. Pei[2], Y. Zheng[3] [1]Department of Toxicology, School of Public Health, Hebei Medical University, Shijiazhuang, China [2]School of Medicine, China Three Gorges University, Yichang, China [3]National Institute for Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China **OSC01-004** **Toxicity of Cerium Dioxide Nanoparticles – Effects from a 90-Day Inhalation Study** D. Schwotzer, M. Niehof, T. Hansen, T. Tillmann, H. Ernst, O. Creutzenberg Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany **OSC01-005** **Co-occurring mycoestrogens formed by {Fusarium} and {Alternaria species} mediate synergistic estrogenic effects** K. Vejdovszky, K. Hahn, B. Warth, D. Marko University of Vienna, Faculty of Chemistry, Dept. of Food Chemistry and Toxicology, Vienna, Austria
16h00 - 18h00 **AUDITORIUM II**	**Symposium S10: Current state of scientific issues in risk assessment of endocrine disruptors and reproductive toxicants** ***Chairs:*** *Hande Gürer-Orhan, Turkey, and Ana Soto, USA* **S10-1** **Performance Of The in vitro assays for testing endocrine disrupters** Hande Gürer Orhan Department of Toxicology, Faculty of Pharmacy, Ege University, Izmir, Turkey **S10-2** **Fetal BPA exposure, development and cancer** Ana M. Soto Department of Integrative Physiology and Pathobiology Tufts University School of Medicine **S10-3** **Utility of AOPs/MOAs in assessing the effects of endocrine disruptors** Alan R Boobis Department of Medicine, Imperial College London, UK **S10-4** **Reproductive toxicity of boric acid and sodium borates** Yalcin Duydu[1], Nursen Basaran[2], Hermann M Bolt[3] [1]Department of Toxicology, Faculty of Pharmacy, Ankara University, Ankara, Turkey [2]Department of Toxicology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

	[3]Leibniz Research Centre for Working Environment and Human Factors (IfADo), Dortmund, Germany
16h00 - 18h00 **AUDITORIUM III**	**Oral Communication Session 2** (10 min presentations) ***Chairs:*** *Suna Sabuncuoğlu, Turkey, and Joao Paulu Texeria, Portugal* **OSC02-009** **Nrf2 and Sirt3 mediated pathways in Patulin-induced mitochondrial dysfunction in kidney cells** Y. Pillay[1], A. Phulukdaree[2], S. Nagiah[1], A. A. Chuturgoon[1] [1]Discipline of Medical Biochemistry, University of KwaZulu-Natal, Durban, South Africa [2]Department of Physiology, University of Pretoria, Pretoria, South Africa **OSC02-008** **Percellome Toxicogenomics of Newly Designed Repeated Dose Study** Jun Kanno[1], Satoshi Kitajima[2], Ken Ichi Aisaki[2] [1]Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan [2]Division of Cellular and Molecular Toxicology, Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan **OSC01-007** **Cytotoxicity and genotoxicity of chlorogenic acid alone or associated with the demethylating drug 5-azacytidine in Jurkat cells** L. C. Hernandes[1], A. R. Machado[1], D. L. Ribeiro[2], A. F. Aissa[1], V. D. Venâncio[1], R. V. Burim[1], M. D. Bianchi[1], L. M. Antunes[1] [1]Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo [2]Departament of Genetics, School of Medicine of Ribeirão Preto, University of São Paulo **OSC02-002** **Deltamethrin produces oxidative stress in the livers and kidneys** B. Nieradko Iwanicka, A. Borzęcki Medical University of Lublin **OSC02-010** **Dioxin-like POPs: induced aryl hydrocarbon receptor transactivity in the Danish pregnant women** M. Long, E. C. Bonefeld Jørgensen Centre for Arctic Health & Molecular Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark **OSC01-002**

Size-dependent genotoxicity of gold nanoparticles in the comet assay and long-term in vivo micronucleus test

L. Hongxia
National Chengdu Center for Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu 610041, P.R. China

OSC01-006
Cholestatic drugs impair bile acid profiles and disposition in HepaRG cells

A. Sharanek[1], A. Burban[1], L. Humbert[2], D. Rainteau[2], A. Guillouzo[1]
[1]Inserm UMR991, Université de Rennes 1, Rennes, France.
[2]ERL Inserm U1157/UMR7203, Faculté de Médecine Pierre et Marie Curie, Site Saint Antoine, Paris, France.

OSC01-011
Introducing a new method for absolute quantification of DNA repair proteins in relation to drug development: LC-MS/MS with isotope dilution

E. Coskun[1], P. Jaruga[1], A. Jemth[2], O. Loseva[2], S. D. Leona[1], A. Tona[3], M. S. Lowenthal[1], P. T. Reddy[1], T. Helleday[2], M. Dizdaroglu[1]
[1]Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, USA
[2]Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
[3]Biosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.

OSC01-001
Use of a human (non- 3D equivalent) skin assay for the detection of adverse reactions and potency

S. S. Ahmed[1], X. N. Wang[2], A. M. Dickinson[1]
[1]Alcyomics Ltd, Bulman House, Regent Centre, Gosforth, Newcastle-upon-Tyne, NE3 3LS, UK
[2]Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK

OSC02-005
Nitro and oxy-PAHs derived from amazon biomass burning and their mutagenicity using different models

S. Batistuzzo[1], M. D. Galvão[2], N. D. Alves[3], P. A. Ferreira[4], S. Caumo[5], P. D. Vasconcellos[5], P. Artaxo[6], S. Hacon[7], D. A. Roubicek[8]
[1]Key-words: Amazon region, particulate matter, reactive oxygen species and cytokines
[2]Programa de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
[3]Faculdade de Medicina da Universidade de São Paulo, FMUSP, Brazil
[4]Universidade Federal do Pará, Campus Universitário de Altamira, Brazil
[5]Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brazil

	[6]Instituto de Física, Universidade de São Paulo, São Paulo, SP, Brazil [7]Escola Nacional de Saúde Pública da Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil [8]Departamento de Análises Ambientais, CETESB, São Paulo, Brazil **OSC02-007** **A Reliable workflow for in silico assessment of genetic toxicity and application to pharmaceutical genotoxic impurities** C. H. Schwab[1], J. F. Rathman[2], J. Marusczyk[1], A. Mostrag[2], B. Bienfait[1], V. Gombar[2], C. Yang[1] [1]Molecular Networks GmbH, Erlangen, Germany [2]Altamira LLC, Columbus, OH USA		
20h00 - 24h00	**Gala Dinner - MONASTERIO MONTE CARMELO**		
Wednesday, 7 September, 2016			
08h00 - 14h00	Congress Registration	08h00 – 14h00	Exhibition
08h00 - 09h00 **AUDITORIUM I**	**Keynote Lecture** ***Chair:*** *Sibel Özden, Turkey* **K-5** **Precautionary Principles in risk management of chemicals and expectations on toxicologists** Heidi Foth, Jan Wiese, Felix Glahn Institute of Environmental Toxicology, Martin Luther University Halle Saale		
09h00 - 11h00 **AUDITORIUM II**	**Symposium S11: Reflections on the application of "Chemical-Specific Adjustment Factors" (CSAF) in quantitative risk assessment** ***Chairs:*** *Richard Brown, Switzerland and Bette Meek, Canada* **S11-1** **Analysis of international experience on CSAFs and potential path forward** Bette Meek McLaughlin Centre, University of Ottawa, Ottawa, Canada **S11-2** **Harmonization of CSAFs with other research efforts including integration with AOP and MOA frameworks** Alan R Boobis Department of Medicine, Imperial College London, UK **S11-3** **Analysis of published Chemical Specific Adjustment Factors (CSAFs) and other data derived factors: obstacles and opportunities**		

	Joanne Caroline English NSF International **S11-4** **From Default Uncertainty Factors to CSAFs: Past, Present and Future in food safety** Jean Lou Christian Michel Dorne European Food Safety Authority, Scientific Committee and Emerging Risks Unit, Parma, Italy **S11-5** Panel Discussion: Enhancing uptake in risk assessment All Speakers
09h00 - 11h00 **AUDITORIUM III**	**Symposium S12: Integration of in vitro systems to predict toxicity from repeated exposure** ***Chairs:*** *Miyoung Yoon, USA, and Bas Blaauboer, The Netherlands* **S12-1** **Overview: integrated in vitro systems for toxicity assessment from repeated exposure** Harvey Clewell ScitoVation, Research Triangle Park, North Carolina, USA **S12-2** **In vitro models of the human airway epithelium for inhalation toxicity testing** Samuel Constant Epithelix, Geneva, Switzerland **S12-3** **Liver bioreactor and incorporation of metabolism and biokinetics into the integrated cell-based toxicity system** Miyoung Yoon[1], Martin Phillips[1], David Billings[1], Pergentino Balbuena[1], Joseph Shim[1], Erin Burgunder[1], Jenny Pedersen[2], Jeffrey Enders[1], Jeffrey Macdonald[3], Melvin Andersen[1], Harvey Clewell[1] [1]ScitoVation, LLC, RTP, NC, USA [2]The Hamner Institutes for Health Sciences, RTP, NC, USA [3]University of North Carolina, Chapel Hill, NC, USA **S12-4** **Integrated Human Multi-Organ Culture Plate for Estimating Systemic Toxicity In Vitro** James M Mckim[1], Heidi Baas[1], Miyoung Yoon[2], Harvey Clewell[2], Melvin E Andersen[2] [1]IonTox, LLC [2]ScitoVation

	S12-5 **Integrating toxicodynamics and biokinetics: Use of in vitro biomarkers** Paul Jennings Department of Physiology and Medical Physics, Medical University of Innsbruck, Austria
09h00 - 11h00 **MADRID**	**Symposium S13: Toxicology of organophosphorus nerve agents (OPA) as the chemical weapons** ***Chairs:*** *Mahdi Balali-Mood, The Netherlands and Shahriar Khateri, The Netherlands* **S13-1** **Clinical management of acute poisoning with organophosphorus nerve agents** Mahdi Balali Mood Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran **S13-2** **Environmental exposure to nerve agents** Slavica Vučinić National Poison Control Centre, Military Medical Academy, Medical faculty University of Defense, Belgrade, Serbia **S13-3** **Nerve agents and chemical disarmament** Shahriar Khateri Organization for the Prohibition of Chemical Weapons, OPCW **S13-4** **Promoting the work of the OPCW through toxicology societies** Aristidis Tsatsakis *Laboratory of Forensic Science&Toxicology, Medical School, University of Crete, Heraklion, Greece*
09h00 - 11h00 **PARIS**	**Workshop W09: Deciphering the role of the aryl hydrocarbon receptor in toxicity and its emerging functions in physiology** ***Chairs:*** *Jan Vondracek, Czechia, and Dieter Schrenk, Germany* **W09-1** **Insights into novel functions of the dioxin receptor in cell differentiation and pluripotency** Pedro M Fernández Salguero[1], Nuria Moreno Marin[1], Antonio Morales Hernandez[1], Ana Nacarino Palma[1], Beroe Paniagua[1], Ascensión Infante Campos[2], Aurea Gomez Duran[2], Inmaculada Catalina Fernández[2], Jaime M. Merino[1] [1]Department of Biochemistry and Molecular Biology, Faculty of Sciences, University of Extremadura, Badajoz, Spain

	[2]Department of Pathology, Infanta Cristina University Medical Center, Badajoz, Spain **W09-2** **The AhR: A regulator of liver fibrosis?** Xavier Coumoul[1], Stéphane Pierre[2], Aline Chevallier[2], Fatima Teixeira Clerc[3], Ariane Ambolet Camoit[2], Linh Chi Bui[2], Anne Sophie Bats[4], Jean Christophe Fournet[5], Pedro Fernandez Salguero[6], Robert Barouki[7], Sophie Lotersztajan[3], Martine Aggerbeck[1] [1]INSERM UMR-S 1124, Toxicologie Pharmacologie et Signalisation Cellulaire, Paris, France [2]Université Paris Descartes, Sorbonne Paris Cité, Paris, France [3]IRMB, INSERM U955, Hopital Henri Mondor, 94010 Creteil, France [4]AP-HP, Hôpital Européen Georges Pompidou, Service de Chirurgie Gynécologique Cancérologique, Paris, France [5]AP-HP, Hôpital Necker-Enfants Malades, Service d'Anatomo-Pathologie, Paris, France [6]Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Extremadura, Badajoz, Spain [7]AP-HP, Hôpital Necker-Enfants Malades, Service de Biochimie Métabolique, Paris, France **W09-3** **Small immune-modulating molecules interacting with the AhR system** Dieter Schrenk Food Chemistry and Toxicology, University of Kaiserslautern, Germany **W09-4** **The aryl hydrocarbon receptor (AhR) and barrier immunity** Charlotte Esser IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany **W09-5** **The intersections of AhR activity and oncogenic signalling** Jan Vondracek[1], Jana Svobodova[1], Jirina Prochazkova[1], Lenka Smerdova[1], Marketa Kabatkova[1], Miroslav Machala[2] [1]Institute of Biophysics, Czech Academy of Sciences, Brno, Czechia [2]Veterinary Research Institute, Brno, Czechia
11h00 - 11h30	Coffee Break
11h30 - 13h30 **AUDITORIUM I**	**Symposium S14: The impact of complexity on chronic disease from exposure to treatment** ***Chairs:*** *Ali Esat Karakaya, Turkey, and Stefano Bonassi, Italy* **S14-1** **Disease networks and predictive methods for clinical data analytics** Cesare Furlanello

	Predictive Models for Biomedicine & Environment, Fondazione Bruno Kessler, Trento, Italy **S14-2** **Emergence of new properties in the investigation of disease aetiology: The contribution of omics** Toby James Athersuch Department of Surgery and Cancer, Imperial College London, London, UK **S14-3** **Advances in multi-omics approaches in chronic disease** Jos Kleinjans Department of Toxicogenomics, Maastricht University, The Netherlands **S14-4** **Integrating genomic and clinical complexity for better patient outcomes** Gerrit Meijer Netherlands Cancer Institute, Amsterdam, Netherlands **S14-5** **The big challenge of complexity for national health systems. How is changing the epidemiology of chronic disease** Stefano Bonassi *IRCCS San Raffaele Pisana, Rome, Italy*
11h30 - 13h30 **AUDITORIUM II**	**Symposium S15: New insights into the toxicity of commonly used pharmaceuticals** ***Chair:*** *Martin Wilks, Switzerland, and Heather Wallace, UK* **S15-1** **Toxicity of the psychotropic drugs: Role of transporters at the blood-brain barrier** Bruno Mégarbane Department of medical and toxicological critical care, Lariboisière Hospital, INSERM U1144, Paris-Diderot University, Paris, France **S15-2** **Paracetamol (acetaminophen) overdose: Are current recommendations for treatment with N-acetylcysteine satisfactory?** Simon Hugh Lynton Thomas Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle NE2 4HH, UK **S15-3** **Colchicine-related life-threatening toxicity: Risk factors and management**

	Philippe Hantson Department of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium **S15-4** **Antidotes for direct oral anticoagulants** Ismail Elalamy Hôspital Tenon UPMC Inserm UMRS-938 Paris, France **S15-5** **Toxicological and pathological findings in opioid-related deaths** Henrik Druid Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
11h30 - 13h30 **AUDITORIUM III**	**Symposium S16: Risk assessment of metals via inhalation: Challenges and new developments** ***Chair:*** *Violaine Verougstraete, Belgium, and Yalçın Duydu, Turkey* **S16-1** **Risk assessment of aetals via inhalation: Challenges and new developments** Steven Verberckmoes Umicore, Brussels, Belgium **S16-2** **Concepts of adversity in inhalation hazard assessment of metals** Gary R Burleson Burleson Research Technologies, Inc., Morrisville, North Carolina, USA **S16-3** **How can bioaccessibility testing add value in the inhalation hazard assessment?** Vanessa Viegas The Cobalt Development Institute, UK **S16-4** **The issue of lung overload of inert insoluble dust. How can prediction modelling contribute in risk assessment?** Len Levy[1], David B Warheit[2] [1]Institute of Environment and Health, Cranfield University, UK [2]1Chemours Company **S16-5** **The human equivalent concentration: A valid approach in extrapolating animal data to the human situation**

	Adriana Oller NiPERA, Inc, Durham, NC, USA **S16-6** **Closing remarks** Steven Verberckmoes *Umicore, Belgium*
11h30 - 13h30 **MADRID**	**Workshop W10: Design and interpretation of testing according to the extended one generation reproductive toxicity study for regulatory use** ***Chair:*** *René Hunziker, Switzerland, and Bruno Hubesch, Belgium* **W10-1** **The extended one generation reproduction toxicity study: Expectations for the new guideline, opportunities, threats** Aldert Piersma, Andre Muller National Institute for Public Health and the Environment RIVM, Bilthoven, The Netherlands **W10-2** **First experiences from testing according to the EOGRST method** Ivana Fegert Regulatory Toxicology Pesticides, BASF SE, Ludwigshafen, Germany **W10-3** **Changes introduced with the new OECD 443 method and implications on the toxicological interpretation** Jochen Buschmann Department of Reproductive Toxicology, Fraunhofer Institute for Toxicology and Experimental Medicine, Germany **W10-4** **Using EOGRTS under REACH, BPD and CLP** Hannele Huuskonen European Chemicals Agency, Helsinki, Finland **W10-5** **The role of the EOGRTS in product safety assessment in industry** René Hunziker Dow Europe GmbH, Cefic LRI, The Switzerland
13h30 - 14h00 **AUDITORIUM I**	**Closing Ceremony and Awards Presentation**